Data / Drug companies / Eribulin mesylate
Eribulin mesylate: 17 companies and 18 products in the FDA NDC directory
Eribulin mesylate is listed in the FDA National Drug Code Directory by 17 companies, with 18 products in commercial distribution. 16 of the products (88.9%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection; solution, and the newest product started marketing on October 19, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 17
- Products
- 18
- Generic (ANDA) products
- 16 (88.9%)
- Application numbers
- 11
- Routes
- Intravenous
- Brand names
- Halaven
- openFDA record search
- api.fda.gov
Companies that list eribulin mesylate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Apotex Corp. | 2 | injection | Generic drugs (ANDA) | March 19, 2025 |
| BSP Pharmaceuticals S.p.A. | 1 | injection | New drug applications (NDA) | April 21, 2017 |
| Baxter Healthcare Company | 1 | injection | Generic drugs (ANDA) | October 1, 2024 |
| BluePoint Laboratories | 1 | solution | Generic drugs (ANDA) | October 8, 2025 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 | injection | Generic drugs (ANDA) | March 4, 2025 |
| Dr. Reddy's Laboratories Inc. | 1 | injection | Generic drugs (ANDA) | January 22, 2026 |
| Eisai Inc. | 1 | injection | New drug applications (NDA) | November 15, 2010 |
| Gland Pharma Limited | 1 | injection | Generic drugs (ANDA) | April 5, 2024 |
| Glenmark Pharmaceuticals Inc., USA | 1 | injection | Generic drugs (ANDA) | August 5, 2025 |
| Hikma Pharmaceuticals USA Inc. | 1 | injection | Generic drugs (ANDA) | June 28, 2024 |
| Kindos Pharmaceuticals Co., Ltd. | 1 | injection | Generic drugs (ANDA) | August 5, 2025 |
| Long Grove Pharmaceuticals, LLC | 1 | solution | Generic drugs (ANDA) | July 22, 2024 |
| Meitheal Pharmaceuticals Inc. | 1 | injection | Generic drugs (ANDA) | October 19, 2026 |
| NorthStar RxLLC | 1 | solution | Generic drugs (ANDA) | December 5, 2025 |
| Sandoz Inc | 1 | injection | Generic drugs (ANDA) | July 7, 2025 |
| Sun Pharmaceutical Industries, Inc. | 1 | injection | Generic drugs (ANDA) | May 15, 2025 |
| XGen Pharmaceuticals DJB, Inc. | 1 | injection | Generic drugs (ANDA) | April 7, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 15 | 83.3% |
| Solution | 3 | 16.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 16 | 88.9% |
| New drug applications (NDA) | 2 | 11.1% |
Pharmacologic classes
| Class | Products |
|---|---|
| Microtubule Inhibitor | 18 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.